The major findings from this study were: (1) TDZD8 reduced L-dopa induced dyskinesia; (2) the effective TDZD8 dose (1 mg/kg or 2 mg/kg) did not interfere with the therapeutic motor effects of L-dopa; (3) TDZD8 reduced L-dopa-induced p-tau, p-DARPP32, p-ERK and PKA over-expression in lesioned striatum; (4) TDZD8 reduced L-dopa-induced FosB mRNA and PPEB mRNA levels in the lesioned striatum; (5) anti-dyskinetic actions of TDZD8 were overcome by D1R agonist. The gene discussed is FOSB; the disease is Dyskinesia.